Table 4.

Summary of the ambulatory BP measurement assessments (mmHg) for patients receiving angiotensin receptor blockers or an angiotensin-converting enzyme inhibitor monotherapy at week 4 (ITT population)

	LSM (SE) change from baseline at week 4
Parameter	N	Lumiracoxib 100 mg od	N	Ibuprofen 600 mg tid	Estimated difference (95% CI)	p-Value
24-h MDABP*
ARB monotherapy	53	−2.5 (0.6)	45	1.3 (0.7)	−3.7 (−5.6, −1.9)	< 0.001
ACEI monotherapy	39	−2.0 (0.9)	37	2.0 (0.9)	−4.0 (−6.6, −1.4)	0.003
Daytime MSABP*
ARB monotherapy	53	−3.1 (1.3)	45	5.2 (1.4)	−8.3 (−12.2, −4.5)	< 0.001
ACEI monotherapy	39	−5.3 (1.6)	37	4.1 (1.6)	−9.4 (−13.9, −4.9)	< 0.001
Night-time MSABP*
ARB monotherapy	53	−3.9 (1.2)	45	3.3 (1.3)	−7.2 (−10.6, −3.8)	< 0.001
ACEI monotherapy	39	−2.9 (1.39)	37	2.5 (1.42)	−5.4 (−9.4, −1.4)	0.008
Daytime MDABP*
ARB monotherapy	53	−2.2 (0.8)	45	1.4 (0.8)	−3.6 (−5.8, −1.4)	0.001
ACEI monotherapy	39	−2.4 (1.1)	37	1.9 (1.1)	−4.3 (−7.4, −1.1)	0.009
Night-time MDABP*
ARB monotherapy	53	−2.8 (0.7)	45	0.9 (0.7)	−3.7 (−5.6, −1.8)	< 0.001
ACEI monotherapy	39	−1.0 (1.0)	37	1.9 (1.0)	−2.8 (−5.7, 0.0)	0.049

^*Change from baseline at week 4.

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BP, blood pressure; CI, confidence interval; ITT, intention-to-treat; LSM, least squares mean; MDABP, mean diastolic ambulatory blood pressure; MSABP, mean systolic ambulatory blood pressure; od, once daily; SE, standard error; tid, three times daily.